Conshohocken biopharmaceutical company Madrigal Pharmaceuticals has named Bill Sibold as the new CEO taking over from Dr. Paul Friedman.
He has also joined the company’s board of directors, writes John George for Philadelphia Business Journal.
Prior to joining Madrigal, Sibold held the positions of executive vice president for specialty care at Sanofi and president of Sanofi North America.
“Madrigal became the industry leader in NASH research and drug development during Friedman’s seven years as CEO. As we prepare for the launch of resmetirom, Bill Sibold brings a different set of skills and experience that will help Madrigal transition from a clinical development-stage company to a full integrated commercial organization,” the company said in a statement.
Resmetirom is a treatment for the inflammatory liver disease.
Madrigal board chairman Julian Baker thanked Friedman for his contributions to the company.
“Paul has built an outstanding team and his many contributions to the biopharmaceutical industry will continue to impact the lives of patients for years to come,” he said.
Read more about Bill Sibold and the future of Madrigal Pharmaceuticals at Philadelphia Business Journal.
____________________________
More on NASH.
